PEPTIDE-FOCUSED STREAMS: OLIGONUCLEOTIDE-FOCUSED … · 2019. 12. 6. · peptide delivery...

Meet Senior Decision Makers

500 senior attendees from leading pharmaceutical, biopharmaceutical,

academics, CRO and solution provider companies will be attending. Meet

Senior VPs, Directors, & Managers with the following job titles:

Discover New Solutions

Formal and informal meeting opportunities offer delegates the

chance to discuss key solutions with leading service providers.

Services to be discussed include:

Day 3: Oligonucleotide Therapeutics & Manufacturing

• Evaluating oligonucleotides as personalised medicines

• Therapeutic antisense oligonucleotides

• Addressing CMC considerations for oligonucleotides

• Process Analytical Technologies

• Toxicology testing for oligos

• Quality assurance

• Case studies from the areas of:

o Oncology

o Genetic disorders

o Cardiovascular diseases

Day 2 Stream 1: Peptide Design, Synthesis, Analytical

Technologies

• Computer-aided design

• Overcoming the challenges in peptide aggregation

• Analytical and bioanalytical strategies for peptide

development

• Early peptide analytics and characterization

• Novel strategies for improving peptide properties: stability

and half-life extension

• Peptide screening

Day 2 Stream 2: Peptide Purification, Manufacturing & Process

Development

• Advances in manufacturing technologies for peptides

• New approaches to manufacture therapeutic peptides

• Regulatory strategies to manufacture peptides on a

commercial scale

• Recent advancements in the processes of manufacturing

peptides

• Advances in the HPLC purification of peptides

•

Day 3 Stream 1: Peptide Therapeutics:

Peptide Therapeutics Case Studies, Immunogenicity & Novel

Disease Treatments

• Therapeutics case studies from the areas of:

o Metabolic disorders:

➢ Obesity

➢ Diabetes

➢ Osteoporosis

o Endocrinology

o Immunology

o Oncology

o Infectious diseases

• Improving the immunogenicity of peptides

• New peptides for novel disease treatments: case studies

• Antimicrobials

Peptide Screening

Peptide Formulation

Peptide Characterisation

Oligonucleotides

Oligo Synthesis

Oligo Characterisation

Peptide Synthesis

Peptide Array Technologies

Display Technologies

Oligo Synthesis

Oligo Design Tools

Therapeutics Development

OLIGONUCLEOTIDE-FOCUSED STREAMS:

Day 2: Oligonucleotide Synthesis, Chemistry, Formulation &

Delivery, Process & Analytical Development

• Advanced synthesis technologies for oligos

• Oral delivery of oligos – overcoming key challenges

• Improving the potency of oligos

• Purification technology development:

o Freeze-drying

o Chromatography

• Impurity analysis

• Designing antisense oligos

• Making stable & quality oligos

PEPTIDE-FOCUSED STREAMS:

Day 1: Kick-Off Session – Turning Challenges to Successes in

Peptide Delivery and Formulation

• Oral delivery of peptides

• Novel formulation strategies for peptides

• Novel peptide delivery strategies

• Enhancing peptide bioavailability

• Updates in stability of peptide therapeutics

• Developing stable peptide formulations

• Peptide display technologies

The event form part of our successful Biologics Series; co-

located with the 13th Annual Proteins & Antibodies Congress

and 2nd Annual Bispecifics in Discovery & Development

Congress.

2020 Speakers Include:

Nigel Richardson Jennifer Franklin Rami Hannoush

McLean Pharma IONIS Pharmaceuticals Genentech

2020 Peptides Confirmed Speakers:

• Thomas Vorherr, Director Peptide Discovery, Novartis

• Michael Agrez, Chief Executive Officer, InterK Peptide Therapeutics

• David Earp, President and Chief Executive Officer, Circle Pharma

• Ali Tavassoli, Founder and Chief Scientific Officer, Curve Therapeutics

• Olivier Kitten, Founder and Chief Executive Officer, Affilogic

• Alex Batchelor, Chief Executive Officer, Orbit Discovery

• Graham Ogg, Founder, Orbit Discovery

• Andrew Young, Chief Scientific Officer, Intarcia Therapeutics

• Laura Itzhaki, Chief Scientific Officer, PolyProx Therapeutics

• Fabrizio Badalassi, Director Chemical Development, Ferring Pharmaceuticals

• Maria Van Dongen, Head of External Innovation, Discovery Sciences, Janssen

• Mathias Schaffrath, Group Head Purification, Sanofi

• Rami Hannoush, Principal Scientist, Genentech

• Jesper Soendergaard Marino, Principal Scientist, Novo Nordisk

• Andreas Hoijer, New Modality Formulation Team Leader, AstraZeneca

• Linda Thunberg, Associate Principal Scientist, AstraZeneca

• Silvia Sonzini, Senior Scientist, AstraZeneca

• Li Li, Principal Scientist, Merck

• Justin Murray, Principal Scientist, Amgen

• Sunay Chankeshwara, Associate Principal Scientist, Senior Expert Peptide Chemistry, AstraZeneca

• Martin Kenworthy, Associate Principal Scientist, AstraZeneca

• Ramesh Kumar, Scientist, Formulation and Drug Product Process Development, MedImmune

• Helen Harrison, Group Leader, Bicycle Therapeutics

• Gemma Mudd, Senior Scientist, Bicycle Therapeutics

• Jette Boll, Senior Scientist, Ferring

• Francesca Macchi, Scientist, Zealand Pharma

• Albert Isidro Llobet, Associate Fellow and Investigator, GlaxoSmithKline

• Victor Terrier, Scientist, Aelin Therapeutics

• Mark Howarth, Professor, University of Oxford

• Aline Miller, Professor, University of Manchester

• Steven Ballet, Professor, Departments of Chemistry and Bio-Engineering Sciences, Free University Brussels

• Derek MacMillan, Reader in Organic Chemistry, University College London

• Andre Cobb, Senior Lecturer in Organic Chemistry, King’s College London

2020 Oligonucleotides Confirmed Speakers:

• Gene Liau, Executive Vice President and Head, Research & Preclinical Development, Stoke Therapeutics

• Ekkehard Leberer, Senior Director, Sanofi

• Matthew Catley, Research Director, MiNA Therapeutics

• Jennifer Franklin, Director, CMC Regulatory Affairs, IONIS Pharmaceuticals

• Annekathrin Haberland, Director, Regulatory Affairs, Berlin Cures

• Nigel Richardson, Head, McLean Pharma

• Michael Keller, Senior Principal Scientist, Pre-Clinical CMC, F. Hoffmann - La Roche

• David Tew, Project Leader and GSK Senior Fellow, GlaxoSmithKline

• Konrad Bleicher, Group Leader, RNA Therapeutics, F.Hoffmann – La Roche

• Nadim Akhtar, Principal Scientist Characterisation & Control Strategy, AstraZeneca

• Hong Jiang, Scientist, Biogen

• Nagy Habib, Professor and Head of the Surgery Hammersmith Campus, Imperial College London

• Jesper Wengel, Professor of Nucleic Acid Center, University of Southern Denmark

• Andre Gerber, Professor of RNA Biology, University of Surrey

• Frank Sobott, Chair in Biomolecular Mass Spectrometry, University of Leeds

• Andrew Livingston, Professor of Chemical Engineering, Queen Mary, University of London

• Afaf El-Sagheer, Professor, University of Oxford

• Haiyan Zhou, Principal Investigator and Group Leader, University College London

• David Williams, Reader in Chemical Biology, University of Sheffield

2020 Biologics Series UK Sponsors:

Platinum Sponsors:

Gold Sponsors:

Benefits to Attending

✓ Hear from and meet with the key innovators in the peptide & oligonucleotide field. Previous attendees included:

Senior Vice President, Ferring Pharmaceuticals; Senior Director, Johnson & Johnson; Director, Novo Nordisk

✓ Discover collaborative solutions to peptide formulation and delivery. Join the kick-off sessions and discuss novel

peptide delivery strategies, oral delivery of peptide-based therapeutics and developing stable peptide formulations

✓ Discuss the latest innovations in peptide synthesis and analytical technologies. Presentations will delve into

oligonucleotide synthesis, advances in HPLC peptide purification, and computer-aided design

✓ New to 2020! Learn more about oligonucleotide synthesis, chemistry, formulation & delivery. Presentations will tap into

advanced synthesis technologies for oligos, improving their potency and addressing the key challenges in their oral

delivery

✓ New to 2020! Gain a comprehensive understanding of oligonucleotide therapeutics & manufacturing. Hear about CMC

considerations for oligos as well as case studies from therapeutic areas such as oncology and infectious diseases

✓ A high-quality programme devised with the help of our esteemed advisory board. Presentations will cover oral

delivery of peptide-based therapeutics, synthesis of oligonucleotides, therapeutic peptide manufacturing

Silver Sponsors:

Bronze Sponsors:

Networking and Programme Sponsors:

7th Annual Peptides & Oligonucleotides Congress

Day One – 27 April 2020


08.00 – 08.30 Registration

08.30 – 11.30 Workshop led by:

Chemical Computing Group

11.00 – 11.30 Registration & Welcome Refreshments

Kick-Off Session – Turning Challenges To Successes In Peptide Delivery and Formulation

• Oral delivery of peptides

• Novel formulation strategies for peptides

• Novel peptide delivery strategies

• Updates in stability of peptide therapeutics

• Developing stable peptide formulations

11.30 – 12.00 Kick Off Session Keynote:

The Obstacles That Bioavailability Represents To Peptide Formulation

Andreas Hoijer, New Modality Formulation Team Leader, AstraZeneca

12.00 – 12.30 Roundtable Discussion

12.30 – 13.15 Lunch

13.15 – 13.45 Designing Peptides For The Medici Drug Delivery System: Integration Of Drug-Device Design

• Attributes and constraints of Intarcia’s mini-osmotic pump

• Strategies for maximizing therapeutic effects, and minimizing adverse effects

Andrew Young, Chief Scientific Officer, Intarcia Therapeutics

13.45 – 14.15 Sponsor Presentation

14.15 – 14.45 Panel Discussion

14.45 – 15.15 The Impact Of Metabolism On Oral Bioavailability Of Peptides

In the first instance, strategies aiming at peptide modifications to maintain or to enhance solubility, while enabling permeability and good exposure upon oral administration are

discussed. The presentation then focuses on our latest insights with respect to metabolism of cyclic peptides, and how hot spots are resolved to achieve excellent oral

bioavailability. In this context, analyses of metabolites, the validation of metabolically stable isosteres for Leu and Pro, and their effect on exposure and oral uptake in rats are

reported.

Thomas Vorherr, Director Peptide Discovery, Novartis

15.15 – 15.45 Developability And Preformulation Of Peptides

Jette Boll, Senior Scientist, Ferring


Day One – 27 April 2020

15.45 – 16.00 Refreshments

16.00 – 16.10 Oxford Global’s Welcome Address

16.10 – 17.10 Welcome Keynote: Biologics Discovery At AstraZeneca

Three case studies will be presented describing different aspects of drug discovery. The first will describe the affinity maturation of an antibody that blocks enzyme function and

compares the co-crystal of the lead mAb with that of the affinity matured variant. The second will describe the challenges relating to intracellular delivery of biologics and how

they can be overcome, and the final case study will illustrate the use of machine learning in antibody discovery.

Tristan Vaughan, Vice President R&D, Antibody Discovery & Protein Engineering, AstraZeneca

17.10 – 18.10 Drinks Reception


Day Two – 28 April 2020


07.30 – 08.20 Registration

08.20 – 08.30 Chairperson’s Welcome Address

Peptide Design, Synthesis & Analytical Technologies

Peptide Purification, Manufacturing & Process

Development

Oligonucleotide Synthesis, Chemistry, Formulation

& Delivery, Process & Analytical Development

08.30 – 09.00 Stream Keynote Address:

Designing Peptide Inhibitors Of E3 Ubiquitin Ligases

I will present our work on peptides designed to inhibit two E3s,

SCF(Skp2) and ACP/C(Cdc20), which are key regulators of the cell

cycle and cell proliferation and important therapeutic targets. The

proteins from which they are derived adopt extended, non-helical

bioactive conformations, presenting challenges for the rational

design of chemical constraints. We have taken a number of

different approaches to overcome these challenges that can be

straightforwardly applied in both biology- and chemistry-focused

labs. I will also discuss how we are exploiting our findings and

methodologies for targeted protein degradation.

Laura Itzhaki, Chief Scientific Officer, PolyProx

Therapeutics

Stream Keynote Address:

Automated Approaches To Peptide Pre-Formulation

And Biophysics

Jesper Soendegaard Marino, Principal Scientist, Novo

Nordisk


Regulatory Agency Questions And Learnings From

Recent Commercial Submissions

Jennifer Franklin, Director, CMC Regulatory Affairs,

IONIS Pharmaceuticals

09.00 – 09.30 Platforms For The Generation And High-Throughput

Screening Of Cyclic Libraries

• High-throughput screening of genetically encoded SICLOPPS

cyclic peptide libraries in cells

• Development of cyclic peptide hits into orally bioavailable

small molecules

• A microfluidics platform for generation and screening of

SICLOPPS cyclic peptide libraries

Ali Tavassoli, Founder and Chief Scientific Officer, Curve

Therapeutics

High Throughput Purification Of Synthetic Peptides

• Purification in 100mg to 1g scale for R&D

• Use of reversed phase chromatography

• High degree of automation and digital workflow from

analysis to freeze-drying

Mathias Schaffrath, Group Head Purification, Sanofi

Disruptive Delivery Technologies Of Antisense

Locked Nucleic Acids

Michael Keller, Senior Principal Scientist, Pre-Clinical

CMC, F. Hoffmann - La Roche

09.30 – 10.00 Solution Provider Presentation

Solution Provider Presentation

For sponsorship opportunities please contact

[email protected]



[email protected]

10.00 – 11.20 Morning Coffee & Refreshments, One to One Meetings x3, Poster Presentation Sessions

mailto:[email protected]




Peptide Design, Synthesis, Analytical Technologies Peptide Purification, Manufacturing & Process

Development



11.20 – 11.50 Challenges In Peptide Analytics

Silvia Sonzini, Senior Scientist, AstraZeneca

Title To Be Confirmed

Alex Batchelor, Chief Executive Officer, Orbit

Discovery

Complete Enzyme Catalysed Oligonucleotide

Synthesis: From Single Nucleotides To Final Product

• Short oligonucleotides are synthesised from simple

nucleotide based starting materials using enzymes by

sequential addition of nucleotides

• The short oligonucleotides thus obtained are

subsequently assembled in a single templated

convergent step

• Template and product are separated using

nanofiltration to produce a high purity final product

resulting in the elimination of all chromatography

throughout the process

David Tew, Project Leader and GSK Senior Fellow,

GlaxoSmtihKline


Disulfide-Rich Peptide Production At AmbioPharm Inc.

• Overview of complex disulfide peptides in the

marketplace

• Synthesis Methods for Peptides containing 1,2,3 & 4

Disulfide Bonds

• Case Studies of 4 different commercial production

campaigns for disulfide-rich peptides

• Short Introduction to Ambiopharm Business Operations

Mike Pennington, Chief Scientific Officer,

AmbioPharm Inc.



[email protected]

12.20 – 12.35





[email protected]



[email protected]

12.50 – 13.50 Lunch, Poster Presentation Sessions







Development



13.50 – 14.20 Overcoming The Challenges In Peptide Aggregation

Francesca Macchi, Scientist, Zealand Pharma

Impact of Trace Level Impurities in Formulation

Excipients on to the Stability of Drug Product

Ramesh Kumar, Scientist, Formulation and Drug

Product Process Development, MedImmune

Risk-based Analytical Control Strategy For Antisense

Oligonucleotides Therapeutics

A phase appropriate and risk-based control strategy was

implemented at Biogen to support a portfolio of ASOs from

the start of clinical development to market distribution.

Due to structural similarities among the ASO molecules,

platform analytical methods are applied as much as

possible. Prior knowledge is leveraged to allow fast

implementation of the essential methods, while continuous

innovation in technologies and practices has resulted in

improvements in analytical capabilities and reduction in

development time. Examples will be discussed to

demonstrate the challenges and progress.

Hong Jiang, Scientist, Biogen

14.20 – 14.50 From Monomer Synthesis To A H10/12 Peptide-Like Helix

• Asymmetric synthesis of novel g-amino acids

• Synthesis and characterisation of foldamers

Andre Cobb, Senior Lecturer in Organic Chemistry, King’s

College London

Chromatographic Purification Of Peptides To Enable

Progress In Early Drug Discovery Projects

• Purification by chromatography is essential for delivery

of potential therapeutic agents to projects, and the

complex impurity pattern from the sequential solid-

phase synthesis of biomolecules requires optimised

chromatographic methods

• The Separation Science Laboratory at AstraZeneca in

Gothenburg has developed a strategy for purification of

peptides, and the potential of using different

chromatographic techniques will be presented

Linda Thunberg, Associate Principal Scientist,

AstraZeneca

Functional Rearrangement Of RNA-Binding Proteins

On Cancer-Related mRNAs Upon Drug Treatment

• Use of antisense oligonucleotides or aptamers for

isolation of mRNAs and bound proteins

• Cisplatin induces post-transcriptional regulation of

cancer-related mRNAs

• RNA-binding proteins modulate drug sensitivity of

cancer cells

Andre Gerber, Professor of RNA Biology, University

of Surrey

14.50 – 15.20

Early Peptide Analytics And Characterisation

Derek McMillan, Reader in Organic Chemistry, UCL

Title To Be Confirmed

Fabrizio Badalassi, Director Chemical Development,

Ferring Pharmaceuticals

Oligonucleotides Synthesis Updates

David Williams, Reader in Chemical Biology,

University of Sheffield

15.20 – 16.20 Afternoon Coffee & Refreshments, One to One Meetings, Poster Presentation Sessions




Development





[email protected]



[email protected]



[email protected]

16.50 – 17.20 Genetic Validation Of Treatment Of Pain With Natural

Peptides

Justin Murray, Principal Scientist, Amgen

Peptide Impurity Control Strategies

• Summary of applicable regulations to peptide drugs

• Challenges in managing commercial supply with lack of

harmonised applicable guidelines

• Overview of peptide manufacturing technologies and

case studies for peptide impurity control

• Conclusions and future perspectives

Martin Kenworthy, Associate Principal Scientist,

AstraZeneca

The Use Of Click Chemistry To Assemble Novel

Modified DNA And RNA Constructs And On New

Methods Of DNA Synthesis

Afaf El-Sagheer, Professor, University of Oxford

17.20 – 17.50 Infinite Affinity Peptide Superglue For Empowering

Proteins And For Global Health

• SpyTag and SnoopTag are peptides allowing autocatalytic

covalent bond formation to their protein partner

• Linking enzymes or antibodies to SpyTag enables their

purification, multiplexing, irreversible anchoring, or

oligomerisation for enhanced function

• Plug-and-display decoration of virus-like particles enhances

vaccine development for viral diseases, cancer and major

global health challenges

Mark Howarth, Professor of Protein Nanotechnology,

University of Oxford

Sustainability Challenges In Peptide Synthesis And

Purification: From R&D To Production

Albert Isidro Llobet, Associate Fellow and Investigator,

GlaxoSmithKline

Structural Analysis Of Oligonucleotides

Frank Sobott, Chair in Biomolecular Mass

Spectrometry, University of Leeds

7th Annual Peptides & Oligonucleotides Congress – Pre-Dinner Roundtable Discussions

17.50 – 18.30

Table 1 – Overcoming Peptide Analytical Challenges

Table 2 – Developing Successful Peptide Therapeutics

Table 3 – Oral Delivery Of Oligonucleotides

18.30 End of Day Two & Congress Dinner





Day Three – 29 April 2020


Peptide Therapeutics

Oligonucleotide Therapeutics & Manufacturing

08.30 – 09.00 Stream Keynote Address:

Antibody-Guided Discovery Of Potent Fusion Inhibitors Of Influenza Virus

Influenza therapeutics with new targets and mechanisms of action are urgently needed to

combat potential new pandemics, emerging viruses, and constantly mutating circulating strains.

We report here on discovery and structural characterization of potent peptidic inhibitors against

influenza hemagglutinin (HA). Guided by the knowledge of the molecular interactions and the

mechanism of anti-stem broadly neutralizing antibodies (bnAbs) CR6261, CR9114 and FI6v3, we

selected and optimized molecules that effectively mimic the bnAb functionality. Our lead

compound potently neutralizes influenza A group 1 viruses by inhibiting HA-mediated fusion. Co-

crystal structures with H1 and H5 HAs reveal that the lead compound recapitulates the bnAb

hotspot interactions.

• Influenza fusion inhibitors

• Antibody-guided discovery

• doi: 10.1126/science.aan0516

Maria Van Dongen, Head External Innovation Discovery Sciences, Janssen


Trends In Developing Oligo Specific CMC Understanding By Exploiting Prior Knowledge

And CMC ‘Hot Topics

There is currently no regulatory guidance specifically for the development of oligonucleotide

therapeutic agents, and as a result existing small molecule guidance is interpreted by sponsors. The

presentation will provide an overview of key CMC which have benefited from harmonization and

sharing of Prior Knowledge. The presentation will also contain examples of industry collaboration and

the future directions and prioritise in publishing data on oligo CMC ‘hot topics’.

Nigel Richardson, Head, McLean Pharma

09.00 – 09.30 Peptide Therapeutics: Novel Peptides For Novel Disease Treatments

Rami Hannoush, Principal Scientist, Genentech

MiRNA Therapeutics: From Bench To Bedside

• Non-coding RNAs play an important role in cellular regulation in health and disease and hence

could be novel targets for future medicines

• MicroRNAs are short non-coding RNAs that regulate biochemical pathways and networks of

pathways by the mechanism of RNA interference (RNAi). MicroRNA-21 has been implicated in

multiple organs as a microRNA associated with fibrotic diseases and cancer

• The presentation will summarize the opportunities and challenges of developing microRNA-based

drugs and will illustrate the successful generation of an anti-fibrotic microRNA-based therapeutic

approach by targeting microRNA-21 with an antisense oligonucleotide (anti-miR-21). This

microRNA-based drug is now in a phase 2 clinical trial for a fibrotic kidney disease called Alport

Syndrome

Ekkehard Leberer, Senior Director, Sanofi




[email protected]

10.00 – 11.00 Morning Coffee & Refreshments, One to One Meetings, Poster Presentation Sessions




Peptide Therapeutics Oligonucleotide Therapeutics & Manufacturing


Leendert van den Bos, Chief Executive Officer, EnzyTag



[email protected]

11.30 – 12.00 Engineering (Hybrid) Peptidomimetics For Improved Pain Treatments

Steven Ballet, Professor, Departments of Chemistry and Bio-Engineering Sciences,

Free University Brussels

The Development Of saRNA Medicines Including The Use Of Medicinal Chemistry And

Drug Delivery Technologies

Matthew Catley, Research Director, MiNA Therapeutics

12.00 – 12.30 Discovery And Optimisation Of Bicycles® As A New Class Of Anti-Infective Agents

• Introduction to Bicycle Therapeutics and Bicycle peptides, a novel therapeutic modality

• Rationale for use of Bicycles as novel anti-infectives

• Summary of discovery and characterisation of Bicycle peptides against a range of bacterial

targets

Helen Harrison, Group Leader, Bicycle Therapeutics

TANGO – Targeted Augmentation Of Nuclear Gene Output For The Treatment Of Genetic

Diseases

Gene Liau, Executive Vice President and Head, Research & Preclinical Development, Stoke

Therapeutics



[email protected]



[email protected]

13.00 – 14.00 Lunch, One to One Meetings x3, Poster Presentation Sessions

14.00 – 14.30

Aelin Therapeutics - Harnessing the power of protein aggregation

• Pept-inTM: a new modality in drug development: the functional inhibition of proteins via induction

of aggregation

• Pept-insTM can treat antibiotic-resistant Gram-negative bacterial infections by inducing toxic

protein aggregation within bacterial cells

• Aelin Therapeutics is developing Pept-insTM against high-value undruggable human targets in other disease fields such as oncology

Victor Terrier, Scientist, Aelin Therapeutics

The Yin & Yang Of Sulfur

Phosphorothioates have been introduced into oligonucleotides even before the advent of ASOs and

turned out to be a key component in most of the clinically validated antisense oligonucleotide drugs.

Here we report our latest observations of backbone modified ASOs with a particular focus on

thiophosphate modifications, including stereo-defined internucleoside linkages.

Konrad Bleicher, Group Leader, RNA Therapeutics, F.Hoffmann – La Roche








15.30 – 16.00 Afternoon Coffee & Refreshments, Poster Presentation Sessions

14.30 – 15.00 Identification And Aptimization Of A Nectin-4 Selective Bicycle For Targeted Delivery

Of Cytotoxic Payloads

• The Bicycle® phage display platform was used to identify Bicycles® which bind selectively

to Nectin-4

• Nectin-4 is a cell adhesion molecule with a restricted distribution in normal tissues, but over

expressed in multiple tumour types

• A lead Bicycle® was chemically optimised to enhance affinity, proteolytic stability and

solubility

• The chemically optimised Bicycle was incorporated into a Bicycle Toxin Conjugate (BTC),

whereby it was conjugated via a cleavable linker to the antimitotic toxin monomethyl

auristatin E (MMAE), giving BT8009

• The pharmacokinetic profile of BT8009 enables a rapid attainment of high levels of MMAE

in tumor with low systemic exposure, thereby sparing healthy tissue

• BT8009 shows excellent efficacy in xenograft models expressing Nectin-4

Gemma Mudd, Senior Scientist, Bicycle Therapeutics

Developing First In Class RNA Oligonucleotide In Patients With Liver Cancer

Nagy Habib, Professor and Head of the Surgery Hammersmith Campus, Imperial College

London

15.00 – 15.30 An Integrated Platform For The Discovery Of Intrinsically Membrane Permeable

Macrocycles Targeting The RXL-Binding Domain Of Cyclin A / Cdk2 And Cyclin E /Cdk2

For The Treatment Of Small Cell Lung Cancer

• Circle has established a platform approach to macrocycle therapeutic discovery emphasizing

intrinsic permeability as a key step in the design workflow

• The platform integrates semi-automated solid phase synthesis of peptide/peptoid hybrids

and both structure-based and ligand-based affinity design methods to target key protein-

protein interactions in oncology

David Earp, President, Chief Executive Officer, Circle Pharma

Lipophilic And Cationic LNA-Based Antisense Oligonucleotides

• Improved pharmacokinetics

• Novel opportunities

• Innovative ASO designs

Jesper Wengel, Professor of Nucleic Acid Center, University of Southern Denmark

16.00 – 16.30 Peptide Therapeutics Application Within Infectious Diseases

Li Li, Principal Scientist, Merck

Nanostar Sieving For Liquid Phase Synthesis Of Oligonucleotides

• More than 130 oligonucleotide drugs are in trials and many of these for mainstream medical

needs. This is creating an imperative to develop scalable technology to manufacturfe oligos at the

multi-ton scale

• Nanostar seiving uses iterative synthesis via protecting groups coupled to nanomembranes to

sieve the growing oligos from reaction debris, so that the whole synthesis is carried out in the

liquid phase

• Oligos produced by nanostar sieving are more than 90%pure before chromatograhpy; the

process can be scaled to any bacth size; and because it is liquid phase process controls can be

used to ensure quality

Andrew Livingston, Professor of Chemical Engineering, Queen Mary, University of London





16.30 – 17.00 Targeted, Controlled And Responsive Therapeutic Delivery Through The Design Of

Self-Assembling Peptide Hydrogels

• Design rules for engineering responsive peptide hydrogels

• Targeting endometriosis with sprayable peptide hydrogels

• Delivery of therapeutics to solid tumors

• Mucoadhesive hydrogels to prolong therapeutic efficacy

Aline Miller, Professor, University of Manchester

Strategies For Identity Testing OF Oligonucleotide Therapeutics

Nadim Akhtar, Principal Scientist Characterisation & Control Strategy, AstraZeneca

17.00 – 17.30 Potential Applications For Immune-Boosting Peptides

• Global unmet needs exist in the fields of cancer immunotherapy, overcoming deleterious

effects of UV irradiation on the skin, development of non-opioid analgesics and drug

addiction

• Peptides that boost the immune system may offer therapeutic options that complement

existing strategies to address the above challenges

Michael Agrez, Chief Executive Officer, InterK Peptide Therapeutics

Evaluating Oligonucleotides As Personalised Medicines

Haiyan Zhou, Principal Investigator and Group Leader, University College London

17.30 – 18.00 Peptide Modalities: From Bench To Humans

• Pulmonary diseases

• Opitcal Imaging chemical tools (peptides)

• Evaluation of drug target engagements and effects in first in-human exploratory study

Sunay Chankeshwara, Associate Principal Scientist, Senior Expert Peptide Chemistry,

AstraZeneca

The Oligonucleotide Agent BC 007 For Neutralization Of Functionally Active Pathogenic

Autoantibodies Directed Against ß 1-Adrenoceptors In Heart Failure Patients – First Phase

II Data

• Functionally active pathogenic autoantibodies (fAAb) against G-protein coupled receptors (fGPCR-

AAbs) are triggers and sustainers of a variety of diseases, mostly affecting the heart and vascular

system as e.g. heart failure (HF; here autoantibodies against the β1-adrenoceptor (fβ1-AAb)) or

pulmonary arterial hypertension (here fAAB against the endothelin ETA-receptor) and sinus

bradycardia (fAAB against the muscarinic M2 receptor)

• As already seen in elderly healthy but fGPCR-AAb positive volunteers in Phase-I, BC 007

neutralizes these fAAbs in patients with progressed HF as well

• Besides this demonstrated mode of action, Phase-I safety tests showed an excellent tolerability,

no clinically relevant side effects. Transient elevated aPTT to subclinical values, paralleling the

infusion, were observed in some subjects

• A two-arm randomized, open-label Phase-IIa study, investigating the temporal persistence of the

fβ1-AAb neutralization, safety and pharmacokinetic in chronic HF patients with reduced ejection

fraction, including twenty β1-AAb positive HF patients and ten positive patients who serve as

controls, is currently running. First efficacy data will be presented

Annekathrin Haberland, Director, Regulatory Affairs, Berlin Cures




18.00 – 18.30 Oral Administration Of Nanofitins For Treatment Of Mucosal Inflammation – A Dual

Targeting Approach

• Nanotifins are small, hyperstable, custom affinity proteins that can be combined to achieve

multispecificity

• Stability includes strong gastric resistance and local activity in the GI tract

• Ongoing development against mucosal targets will be shared

Olivier Kitten, Founder, Chief Executive Officer, Affilogic

De-Orphanizing Primary T Cells Using DNA-Encoded Peptide-MHC Libraries On Beads

Graham Ogg, Founder, Orbit Discovery

18.30 End of Conference

I cannot attend but would like to purchase access to the following:

Access to the online conference presentations £499 plus VAT VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

Biologics Series

13th Annual Proteins & Antibodies Congress | 7th Annual Peptides & Oligonucleotides Congress 2nd Annual Bispecifics in Discovery & Development Congress

27 - 29 April 2020, Novotel London West, London, UK www.oxfordglobal.co.uk/biologics-series/

HOW TO REGISTER: FAX your booking form to +44(0)1865 689120 | PHONE on +44(0)1865 248455 | EMAIL: [email protected]

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Series, presentations and panel sessions, scheduled one-to-one meetings and networking/social events, Series and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser.

An admin surcharge of £50 plus VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

Acceptance of a Complimentary Pass If you are offered a free delegate pass and you are unable to attend the Series, you may nominate a substitute of equal standing (in terms of business and financial responsibility). A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in ad-vance in order to avoid a non-attendance charge of £200 plus VAT being applied. Your complimentary delegate place is not officially confirmed until we have had chance to check that you qualify for the complimentary pass. Please do not make any travel arrangements before we have confirmed acceptance of your application. We will not be liable for any expenses incurred.

Delegate Registration Form Each Delegate must complete the online delegate registration form issued by the Organiser on receipt of the Delegate Booking Form. This information will only be used for the organisation of the Series, for material produced for Delegates and Sponsors and to facilitate the networking sessions.

Cancellation and Curtailment If a Registered Delegate is unable to attend the Series, he/she may nominate a substitute of equal standing within their Company. A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid cancellation charges being applied. Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee / 25% refund Less than 3 months prior to the event Full cancellation fee / No refund

Data Protection The data controller is the organiser (Oxford Global Marketing Ltd). Registration details will be retained and used in accordance with our privacy policy. Your information may be shared with selected partners and contractors, solely for the for the purposes of the event. Please note: If you attend an event then a sponsor or exhibitor may scan your badge. This is the equivalent to handing over your business card. Should you allow your badge to be scanned then Oxford Global will share your Personal Information with the relevant sponsor or exhibitor. If you register for a sponsor-led workshop or session (by actively selecting this option at the point of registration or allowing your badge to be scanned on entry to the session), you are agreeing to share your personal information with the named sponsor

Miscellaneous The Organiser will determine the scope and content of Series events, seminars, workshops and activities throughout the Series. The Organiser reserves the right to cancel the Series without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Series, the Organiser reserves the right to transfer this Booking to another Series within the same sector to be held within twelve months. Should another Series in the same sector not be available within this period, the Booking Fee will be refunded. For promotional purposes, there may be professional photography and video production taking place during the Series. Delegates who do not wish to be filmed or recorded should advise the organisers by email to [email protected] prior to the event. These terms and conditions are binding upon the delegate submitting a registration form.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]

Delegate Details

Terms & Conditions of Booking

I agree to the above Terms and Conditions

Registration Fees

Documentation

How to Pay (choose one of the following payment options)

I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies) 2-day pass £899 plus VAT 1-day pass £599 plus VAT Day 1 (with complimentary access to the pre-event workshop) Day 2 Day 3 Academic Delegates 2-day pass £520 plus VAT 1-day pass £320 plus VAT Day 1 (with complimentary access to the pre-event workshop) Day 2 Day 3 Vendor Delegates (CROs, Consultants, Technology and Service Providers) Series Only £1750 plus VAT Poster Presentation £250 plus VAT PROMOTIONAL LITERATURE DISTRIBUTION Distribution of your company’s promotional literature to all Series attendees £999 plus VAT

Number of delegates:

Industry del(s) Academic dels(s) Vendor dels(s)

Special Offer: 3 for 2 Offer is only valid on the Series and for those registering at Industry or Academic rates

Please choose one of the following payment options:

CREDIT CARD:

An Oxford Global representative will contact you directly following return of contract / booking form to process card payment. If payment will be made by a colleague within your company, please complete the following;

Card Payment Contact Name: ___________________________________

Phone Number: _________________________________________________ INVOICE:

Invoice Address (if different from above) ________________________

__________________________________________________________________

__________________________________________________________________

*Please note there is a £50 plus VAT handling charge for payment via invoice

Please complete fully and clearly. Please photocopy for additional delegates. Please tick which event(s) in the Series you are interested in: Proteins & Antibodies Congress Bispecifics Congress Peptides & Oligonucleotides Congress Title:_____ Forename:__________________ Surname:__________________ Job Title:___________________________________________________________ Company/Organisation:___________________________________________ Email:_____________________________________________________________ Address:___________________________________________________________ Postcode: ________________________ Country: _________________________ Direct Telephone _______________ Direct Fax: ________________ Mobile: ________________________ Switchboard: _____________ Signature: ______________________ Date: ___________________________

https://www.oxfordglobal.co.uk/biologics-series/




PEPTIDE-FOCUSED STREAMS: OLIGONUCLEOTIDE-FOCUSED … · 2019. 12. 6. · peptide delivery...

Documents

Transcript of PEPTIDE-FOCUSED STREAMS: OLIGONUCLEOTIDE-FOCUSED … · 2019. 12. 6. · peptide delivery...